Argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018


Argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, March 1, 2018 at 3:00 pm CET (9:00 am ET) to discuss its 2017 financial results and provide a fourth quarter business update

To participate in the conference call, please select your phone number below, and use the confirmation code 6683242. The webcast may be accessed on the homepage of the argenx website at or by clicking here. A replay of the webcast will also be available at the argenx website.

Dial-in numbers:
Please dial in 5-10 minutes prior to 3 p.m. CET/ 9 a.m. EDT using the number and conference ID below.

Confirmation Code: 6683242
Belgium 0800 58228
Belgium +32 (0)2 404 0659
France 0805 101 219
France +33 (0)1 76 77 22 74
Netherlands 0800 023 1436
Netherlands +31 (0) 20 721 9251
United Kingdom 0800 358 6377
United Kingdom +44 (0)330 336 9105
United States 888-394-8218
United States +1 323-794-2149

A question and answer session will follow the presentation of the results. Go to to access the live audio webcast. The archived webcast will also be available (90 days) for replay shortly after the close of the call from the "Downloads" section of the argenx website.


Argenx a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates.



Interested in a regular update of the Life Sciences and biotech sector in Flanders?